Jill Gilbert

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. ncbi A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck
    Jill Gilbert
    Vanderbilt University School of Medicine, Nashville, TN, USA
    Clin Cancer Res 18:1735-42. 2012
  2. ncbi Depression in patients with head and neck cancer and a functional genetic polymorphism of the serotonin transporter gene
    Jill Gilbert
    Department of Medicine, Hematology Oncology Vanderbilt University School of Medicine Vanderbilt Ingram Cancer Center, 777 Preston Research Building, Nashville, Tennessee, USA
    Head Neck 34:359-64. 2012
  3. ncbi Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer
    Jill Gilbert
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6307, USA
    Cancer 118:1007-13. 2012
  4. ncbi Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck
    Jill Gilbert
    Division of Hematology and Oncology, Department of Medicine, Vanderbilt University School of Medicine, 2220 Pierce Avenue, 777 PRB, Nashville, TN 37232, USA
    Cancer 113:186-92. 2008
  5. ncbi Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck
    Jill Gilbert
    Division of Hematology and Oncology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Clin Adv Hematol Oncol 4:611-9. 2006
  6. ncbi Vanderbilt Head and Neck Symptom Survey version 2.0: report of the development and initial testing of a subscale for assessment of oral health
    Emily Cooperstein
    Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Head Neck 34:797-804. 2012
  7. ncbi Reliability and validity of the Vanderbilt Head and Neck Symptom Survey: a tool to assess symptom burden in patients treated with chemoradiation
    Barbara A Murphy
    Department of Medicine, Vanderbilt University Medical Center, USA
    Head Neck 32:26-37. 2010
  8. ncbi Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer
    Roberto Diaz
    Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Int J Radiat Oncol Biol Phys 77:468-76. 2010
  9. ncbi Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Cancer Epidemiol Biomarkers Prev 19:358-65. 2010
  10. ncbi Evolution of clinical trials in head and neck cancer
    Eddy S Yang
    Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN 37232 5671, USA
    Crit Rev Oncol Hematol 71:29-42. 2009

Collaborators

Detail Information

Publications24

  1. ncbi A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck
    Jill Gilbert
    Vanderbilt University School of Medicine, Nashville, TN, USA
    Clin Cancer Res 18:1735-42. 2012
    ..We also sought evidence of biologic activity of erlotinib alone using serial 18-FDG positron emission tomography (PET) imaging...
  2. ncbi Depression in patients with head and neck cancer and a functional genetic polymorphism of the serotonin transporter gene
    Jill Gilbert
    Department of Medicine, Hematology Oncology Vanderbilt University School of Medicine Vanderbilt Ingram Cancer Center, 777 Preston Research Building, Nashville, Tennessee, USA
    Head Neck 34:359-64. 2012
    ..The purpose of this study was to show the evaluated depression in patients with head and neck cancer and a possible association with the 5-HTTLPR...
  3. ncbi Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer
    Jill Gilbert
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6307, USA
    Cancer 118:1007-13. 2012
    ..This phase 2 trial evaluated the tolerability and clinical efficacy of the combination of oxaliplatin and pemetrexed as an induction chemotherapy regimen in locally advanced head and neck squamous cell carcinoma (HNSCC)...
  4. ncbi Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck
    Jill Gilbert
    Division of Hematology and Oncology, Department of Medicine, Vanderbilt University School of Medicine, 2220 Pierce Avenue, 777 PRB, Nashville, TN 37232, USA
    Cancer 113:186-92. 2008
    ..Thus, new agents are needed. The authors report the results of a phase II trial of irinotecan and cisplatin in patients with metastatic or recurrent HNC...
  5. ncbi Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck
    Jill Gilbert
    Division of Hematology and Oncology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Clin Adv Hematol Oncol 4:611-9. 2006
    ..The addition of novel, targeted agents to traditional therapies holds promise for clinical benefit. This review will focus on new agents that are promising and their potential role in the treatment of SCCHN...
  6. ncbi Vanderbilt Head and Neck Symptom Survey version 2.0: report of the development and initial testing of a subscale for assessment of oral health
    Emily Cooperstein
    Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Head Neck 34:797-804. 2012
    ..We report development of an oral health outcome subscale for the Vanderbilt Head and Neck Symptom Survey (VHNSS)...
  7. ncbi Reliability and validity of the Vanderbilt Head and Neck Symptom Survey: a tool to assess symptom burden in patients treated with chemoradiation
    Barbara A Murphy
    Department of Medicine, Vanderbilt University Medical Center, USA
    Head Neck 32:26-37. 2010
    ....
  8. ncbi Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer
    Roberto Diaz
    Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Int J Radiat Oncol Biol Phys 77:468-76. 2010
    ....
  9. ncbi Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Cancer Epidemiol Biomarkers Prev 19:358-65. 2010
    ....
  10. ncbi Evolution of clinical trials in head and neck cancer
    Eddy S Yang
    Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN 37232 5671, USA
    Crit Rev Oncol Hematol 71:29-42. 2009
    ..Emerging new technologies such as intensity modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) will also be reviewed. Functional assessments and quality of life issues will be addressed...
  11. ncbi Symptom control issues and supportive care of patients with head and neck cancers
    Barbara A Murphy
    Vanderbilt University Medical Center, Division of Hematology Oncology, Nashville, TN 37232, USA
    Clin Adv Hematol Oncol 5:807-22. 2007
    ..Additionally, the pretreatment and during-treatment evaluation of dental health, as well as posttreatment dental care, are described...
  12. ncbi Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma
    Hiromitsu Hatakeyama
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
    PLoS ONE 5:e12702. 2010
    ....
  13. ncbi Dysphagia in head and neck cancer patients treated with radiation: assessment, sequelae, and rehabilitation
    Barbara A Murphy
    Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, TN 37232 6307, USA
    Semin Radiat Oncol 19:35-42. 2009
    ....
  14. ncbi Systemic and global toxicities of head and neck treatment
    Barbara A Murphy
    Vanderbilt University Medical Center, Nashville, TN 37232 6307, USA
    Expert Rev Anticancer Ther 7:1043-53. 2007
    ..It is important for clinicians to be aware of these late effects in order to provide patients with appropriate support services and referrals. This paper examines the global and systemic effects of therapy...
  15. ncbi Factors associated with the career choices of hematology and medical oncology fellows trained at academic institutions in the United States
    Leora Horn
    Vanderbilt Ingram Cancer Center, Nashville, TN, USA
    J Clin Oncol 29:3932-8. 2011
    ....
  16. ncbi Organ preservation for cancer of the larynx: current indications and future directions
    Jill Gilbert
    Louisiana State University Health Sciences Center, Stanley S Scott Cancer Center, New Orleans, LA, USA
    Semin Radiat Oncol 14:167-77. 2004
    ..It remains to be seen whether such interventions can improve on the excellent locoregional control shown in the landmark Intergroup trial...
  17. ncbi Organ preservation trials for laryngeal cancer
    Jill Gilbert
    Louisiana State University, Health Sciences Center Stanley, C. Scott Cancer Center, 433 Bolivar Street, New Orleans, LA 70112, USA
    Otolaryngol Clin North Am 35:1035-54, vi. 2002
    ....
  18. ncbi Prevalence and epidemiology of hepatitis C virus in patients with squamous cell carcinoma of the head and neck
    James Nobles
    Department of Otolaryngology and Biocommunication, Hematology and Oncology Division, Louisiana State University Health Sciences Center-New Orleans, 533 Bolivar Street, New Orleans, LA 70112, U.S.A
    Laryngoscope 114:2119-22. 2004
    ..These patients presented at an earlier age but had similar presentation with respect to site and stage. More research is needed to determine the significance of HCV infection in this patient population...
  19. ncbi Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies
    Michelle A Rudek
    Division of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    J Clin Oncol 23:3906-11. 2005
    ..To characterize the pharmacokinetic behavior of 5-azacitidine (5-AC), a cytidine nucleoside analog, when given with phenylbutyrate, a histone deaceytlase inhibitor...
  20. ncbi The clinical application of targeting cancer through histone acetylation and hypomethylation
    Jill Gilbert
    Division of Oncology and Hematology, Stanley S Scott Cancer Center, Louisiana State University, New Orleans, Louisiana 70112, USA
    Clin Cancer Res 10:4589-96. 2004
    ..Reversal of these epigenetic processes and up-regulation of genes important to prevent or reverse the malignant phenotype has therefore become a new therapeutic target in cancer treatment...
  21. ncbi A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies
    Jill Gilbert
    Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA
    Invest New Drugs 24:499-508. 2006
    ..This was correlated with higher CNDAC Cmax and AUC values. No tumor responses were noted in this heavily pretreated population. However, given the ease of administration and tolerability, further investigation of this agent is warranted...
  22. ncbi Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group
    Jill Gilbert
    Louisiana State University Medical Center, New Orleans, Louisiana, USA
    Head Neck 28:197-204. 2006
    ..The poor response rate in adenoid cystic carcinoma is consistent with prior reports in this chemoresistant histologic subtype...
  23. ncbi Outcome analysis of patients with squamous cell carcinoma of the head and neck and hepatitis C virus
    Jason Hunt
    Department of Otolaryngology and Biocommunication, Biostatistics Program, Hematology and Oncology Division at the Louisiana State University Health Sciences Center in New Orleans, 70112, USA
    Laryngoscope 115:1882-6. 2005
    ..Patients who were seropositive for HCV had comparable serum albumin levels as well as serum hematocrit when compared with HCV negative patients...
  24. ncbi The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms
    Jennifer Bolt
    Stanley S. Scott Cancer Center, LSU Health Sciences Center, New Orleans, LA, USA
    Oral Oncol 41:1013-20. 2005
    ..These findings indicate that molecular events resulting in inactivation of the ATM/p53 pathway are common in SCCHN and can arise by a number of distinct mechanisms...